Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SurveY Followed by a Retrospective Chart Review to Describe the Key Factors Leading to Physician's Decision to Treat Patients at High and Very High Cardiovascular Risk With hyperchOlesterolemia or Mixed Dyslipidemia With NUSTENDI® (Fixed Dose Combination of Bempedoic Acid 180mg and Ezetimibe 10mg) as add-on to Treatment With Maximally Tolerated Statin Therapy in Routine Clinical Practice

NCT05546398 is registered in ClinicalTrials.gov with Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company as lead sponsor.

NCT NCT05546398
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05546398 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SurveY Followed by a Retrospective Chart Review to Describe the Key Factors Leading to Physician's Decision to Treat Patients at High and Very High Cardiovascular Risk With hyperchOlesterolemia or Mixed Dyslipidemia With NUSTENDI® (Fixed Dose Combination of Bempedoic Acid 180mg and Ezetimibe 10mg) as add-on to Treatment With Maximally Tolerated Statin Therapy in Routine Clinical Practice
Lead sponsor
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Phase
Observational
Overall status
Completed
Start date
April 22, 2022
Completion date
November 17, 2022
Enrollment
500 (actual)
Sites
63

Conditions

As the registry lists them; a condition with its own page is linked.

hypercholesterolemia, mixed dyslipidemia